nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—IRAK1—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.0211	0.0211	CbGpPWpGaD
Afatinib—ERBB2—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0197	0.0197	CbGpPWpGaD
Afatinib—ERBB4—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0194	0.0194	CbGpPWpGaD
Afatinib—ERBB2—PI-3K cascade—FRS2—nasal cavity cancer	0.0178	0.0178	CbGpPWpGaD
Afatinib—ERBB4—PI-3K cascade—FRS2—nasal cavity cancer	0.0175	0.0175	CbGpPWpGaD
Afatinib—ERBB2—PI3K/AKT activation—FRS2—nasal cavity cancer	0.0173	0.0173	CbGpPWpGaD
Afatinib—ERBB2—GAB1 signalosome—FRS2—nasal cavity cancer	0.0172	0.0172	CbGpPWpGaD
Afatinib—ERBB4—PI3K/AKT activation—FRS2—nasal cavity cancer	0.0171	0.0171	CbGpPWpGaD
Afatinib—ERBB4—GAB1 signalosome—FRS2—nasal cavity cancer	0.0169	0.0169	CbGpPWpGaD
Afatinib—ERBB2—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0168	0.0168	CbGpPWpGaD
Afatinib—ERBB4—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0166	0.0166	CbGpPWpGaD
Afatinib—IRAK1—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.0165	0.0165	CbGpPWpGaD
Afatinib—ABL1—Neurotrophic factor-mediated Trk receptor signaling—FRS2—nasal cavity cancer	0.0147	0.0147	CbGpPWpGaD
Afatinib—ERBB2—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.0133	0.0133	CbGpPWpGaD
Afatinib—ERBB4—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.0131	0.0131	CbGpPWpGaD
Afatinib—EGFR—SHP2 signaling—FRS2—nasal cavity cancer	0.0131	0.0131	CbGpPWpGaD
Afatinib—ERBB2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.0127	0.0127	CbGpPWpGaD
Afatinib—LCK—SHP2 signaling—FRS2—nasal cavity cancer	0.0126	0.0126	CbGpPWpGaD
Afatinib—ERBB4—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.0125	0.0125	CbGpPWpGaD
Afatinib—ERBB2—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0125	0.0125	CbGpPWpGaD
Afatinib—ERBB4—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0123	0.0123	CbGpPWpGaD
Afatinib—ERBB2—Downstream signal transduction—FRS2—nasal cavity cancer	0.0119	0.0119	CbGpPWpGaD
Afatinib—ERBB2—Signaling by FGFR—FRS2—nasal cavity cancer	0.0119	0.0119	CbGpPWpGaD
Afatinib—ERBB2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.0118	0.0118	CbGpPWpGaD
Afatinib—ERBB2—DAP12 signaling—FRS2—nasal cavity cancer	0.0118	0.0118	CbGpPWpGaD
Afatinib—ERBB4—Downstream signal transduction—FRS2—nasal cavity cancer	0.0118	0.0118	CbGpPWpGaD
Afatinib—ERBB4—Signaling by FGFR—FRS2—nasal cavity cancer	0.0117	0.0117	CbGpPWpGaD
Afatinib—ERBB4—Signaling by ERBB2—FRS2—nasal cavity cancer	0.0116	0.0116	CbGpPWpGaD
Afatinib—ERBB2—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.0116	0.0116	CbGpPWpGaD
Afatinib—ERBB4—DAP12 signaling—FRS2—nasal cavity cancer	0.0116	0.0116	CbGpPWpGaD
Afatinib—ERBB4—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.0114	0.0114	CbGpPWpGaD
Afatinib—ERBB2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0111	0.0111	CbGpPWpGaD
Afatinib—ERBB2—DAP12 interactions—FRS2—nasal cavity cancer	0.0111	0.0111	CbGpPWpGaD
Afatinib—ERBB2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0111	0.0111	CbGpPWpGaD
Afatinib—ERBB2—Signaling by EGFR—FRS2—nasal cavity cancer	0.011	0.011	CbGpPWpGaD
Afatinib—ERBB4—DAP12 interactions—FRS2—nasal cavity cancer	0.0109	0.0109	CbGpPWpGaD
Afatinib—ERBB4—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0109	0.0109	CbGpPWpGaD
Afatinib—ERBB4—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0109	0.0109	CbGpPWpGaD
Afatinib—ERBB2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.0109	0.0109	CbGpPWpGaD
Afatinib—ERBB2—Signaling by PDGF—FRS2—nasal cavity cancer	0.0108	0.0108	CbGpPWpGaD
Afatinib—ERBB4—Signaling by EGFR—FRS2—nasal cavity cancer	0.0108	0.0108	CbGpPWpGaD
Afatinib—ERBB4—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Afatinib—ERBB4—Signaling by PDGF—FRS2—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Afatinib—ERBB2—B Cell Activation—FRS2—nasal cavity cancer	0.0102	0.0102	CbGpPWpGaD
Afatinib—ERBB4—B Cell Activation—FRS2—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Afatinib—ERBB2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0098	0.0098	CbGpPWpGaD
Afatinib—BLK—B Cell Activation—FRS2—nasal cavity cancer	0.00971	0.00971	CbGpPWpGaD
Afatinib—ERBB4—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00966	0.00966	CbGpPWpGaD
Afatinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00953	0.00953	CbGpPWpGaD
Afatinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00919	0.00919	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.00874	0.00874	CbGpPWpGaD
Afatinib—EGFR—PI-3K cascade—FRS2—nasal cavity cancer	0.00859	0.00859	CbGpPWpGaD
Afatinib—EGFR—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00838	0.00838	CbGpPWpGaD
Afatinib—EGFR—GAB1 signalosome—FRS2—nasal cavity cancer	0.00832	0.00832	CbGpPWpGaD
Afatinib—LCK—PI-3K cascade—FRS2—nasal cavity cancer	0.00828	0.00828	CbGpPWpGaD
Afatinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00813	0.00813	CbGpPWpGaD
Afatinib—LCK—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00808	0.00808	CbGpPWpGaD
Afatinib—LCK—GAB1 signalosome—FRS2—nasal cavity cancer	0.00801	0.00801	CbGpPWpGaD
Afatinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00783	0.00783	CbGpPWpGaD
Afatinib—ERBB2—Signaling by NGF—FRS2—nasal cavity cancer	0.00754	0.00754	CbGpPWpGaD
Afatinib—ERBB4—Signaling by NGF—FRS2—nasal cavity cancer	0.00743	0.00743	CbGpPWpGaD
Afatinib—EGFR—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00642	0.00642	CbGpPWpGaD
Afatinib—LCK—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00619	0.00619	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00614	0.00614	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00604	0.00604	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00592	0.00592	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00582	0.00582	CbGpPWpGaD
Afatinib—EGFR—Downstream signal transduction—FRS2—nasal cavity cancer	0.00577	0.00577	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR—FRS2—nasal cavity cancer	0.00574	0.00574	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00572	0.00572	CbGpPWpGaD
Afatinib—EGFR—DAP12 signaling—FRS2—nasal cavity cancer	0.00569	0.00569	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00561	0.00561	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—FRS2—nasal cavity cancer	0.00556	0.00556	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—FRS2—nasal cavity cancer	0.00554	0.00554	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00551	0.00551	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—FRS2—nasal cavity cancer	0.00548	0.00548	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—FRS2—nasal cavity cancer	0.00545	0.00545	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.0054	0.0054	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—FRS2—nasal cavity cancer	0.00535	0.00535	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00535	0.00535	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00535	0.00535	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—FRS2—nasal cavity cancer	0.0053	0.0053	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00526	0.00526	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—FRS2—nasal cavity cancer	0.00523	0.00523	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00516	0.00516	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00516	0.00516	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—FRS2—nasal cavity cancer	0.00516	0.00516	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—FRS2—nasal cavity cancer	0.00511	0.00511	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00507	0.00507	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—FRS2—nasal cavity cancer	0.00504	0.00504	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—FRS2—nasal cavity cancer	0.00495	0.00495	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—FRS2—nasal cavity cancer	0.00477	0.00477	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00474	0.00474	CbGpPWpGaD
Afatinib—PHKG2—Disease—FRS2—nasal cavity cancer	0.00466	0.00466	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00457	0.00457	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—FRS2—nasal cavity cancer	0.0043	0.0043	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—FRS2—nasal cavity cancer	0.00424	0.00424	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—FRS2—nasal cavity cancer	0.00413	0.00413	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—FRS2—nasal cavity cancer	0.00407	0.00407	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00391	0.00391	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—FRS2—nasal cavity cancer	0.00365	0.00365	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—FRS2—nasal cavity cancer	0.00351	0.00351	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—FRS2—nasal cavity cancer	0.00311	0.00311	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00275	0.00275	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00271	0.00271	CbGpPWpGaD
Afatinib—ERBB2—Immune System—FRS2—nasal cavity cancer	0.0025	0.0025	CbGpPWpGaD
Afatinib—ERBB4—Immune System—FRS2—nasal cavity cancer	0.00247	0.00247	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Afatinib—BLK—Immune System—FRS2—nasal cavity cancer	0.00237	0.00237	CbGpPWpGaD
Afatinib—ERBB2—Disease—FRS2—nasal cavity cancer	0.00231	0.00231	CbGpPWpGaD
Afatinib—ERBB4—Disease—FRS2—nasal cavity cancer	0.00228	0.00228	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00225	0.00225	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—FRS2—nasal cavity cancer	0.00208	0.00208	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—FRS2—nasal cavity cancer	0.002	0.002	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—FRS2—nasal cavity cancer	0.002	0.002	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00199	0.00199	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00192	0.00192	CbGpPWpGaD
Afatinib—IRAK1—Immune System—FRS2—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—FRS2—nasal cavity cancer	0.00162	0.00162	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—FRS2—nasal cavity cancer	0.0016	0.0016	CbGpPWpGaD
Afatinib—ABL1—Immune System—FRS2—nasal cavity cancer	0.00142	0.00142	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL11—nasal cavity cancer	0.00133	0.00133	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL11—nasal cavity cancer	0.00128	0.00128	CbGpPWpGaD
Afatinib—EGFR—Immune System—FRS2—nasal cavity cancer	0.00121	0.00121	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FRS2—nasal cavity cancer	0.00117	0.00117	CbGpPWpGaD
Afatinib—LCK—Immune System—FRS2—nasal cavity cancer	0.00117	0.00117	CbGpPWpGaD
Afatinib—EGFR—Disease—FRS2—nasal cavity cancer	0.00112	0.00112	CbGpPWpGaD
Afatinib—LCK—Disease—FRS2—nasal cavity cancer	0.00108	0.00108	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FRS2—nasal cavity cancer	0.000783	0.000783	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FRS2—nasal cavity cancer	0.000754	0.000754	CbGpPWpGaD
